Evidence map›Paper›PMID 41900977›Full record

ArticleLife (Basel, Switzerland)2026

Clinical Prediction of Functional Decline in Multiple Sclerosis Using Volumetry-Based Synthetic Brain Networks.

Alin Ciubotaru, Alexandra Maștaleru, Thomas Gabriel Schreiner, Cristiana Filip, Roxana Covali, Laura Riscanu, Robert-Valentin Bilcu, Laura-Elena Cucu, Sofia Alexandra Socolov-Mihaita, Diana Lăcătușu and 6 more

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Alin CiubotaruGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0009-0003-2079-2383
Alexandra MaștaleruGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-0008-9696
Thomas Gabriel SchreinerGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-4495-4004
Cristiana FilipGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Roxana CovaliDepartment of Radiology, Biomedical Engineering Faculty, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-7386-0859
Laura RiscanuDepartment of Morphofunctional Sciences, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0001-5241-0181
Robert-Valentin BilcuDoctoral School, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Laura-Elena CucuDoctoral School, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0009-0000-1544-1325
Sofia Alexandra Socolov-MihaitaDoctoral School, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Diana LăcătușuDepartment of Pharmacological Phisics, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0009-0006-8719-8268
Florina CrivoiDepartment of Pharmacological Phisics, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Albert VamanuBasic and Clinical Neuroscience Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.
Ioana MartuGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Lucia Corina Dima-CozmaGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.
Romica Sebastian CozmaGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.ORCID 0000-0002-3768-6232
Oana-Roxana Bitere-PopaGrigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDisability progression in multiple sclerosis (MS) is increasingly recognized as a consequence of large-scale brain network disruption rather than isolated regional damage. Although diffusion tensor imaging (DTI) is the reference method for assessing structural connectivity, its limited availability restricts widespread clinical application. There is therefore a critical need for alternative approaches capable of capturing network-level alterations using routinely acquired MRI data.

objectiveThis study aimed to determine whether synthetic structural connectivity matrices derived from standard regional volumetric MRI can capture clinically meaningful network alterations in MS and predict subsequent functional progression, particularly upper limb decline.

methodsRegional brain volumetry was obtained from routine T1-weighted MRI using an automated, clinically approved volumetric pipeline. Synthetic structural connectivity matrices were generated by integrating principles of structural covariance, distance-dependent connectivity, and disease-specific vulnerability patterns. Graph-theoretical network metrics were extracted to characterize global and regional topology. Machine learning models including logistic regression, support vector machines, random forests, and gradient boosting were trained to predict clinical progression defined by worsening on the 9-Hole Peg Test. Dimensionality reduction was performed using principal component analysis, and model performance was evaluated using balanced accuracy, AUC-ROC, and resampling-based validation. Feature importance analyses were conducted to identify network vulnerability patterns.

resultsSynthetic connectivity networks exhibited biologically plausible properties, including preserved but attenuated small-world organization. Global efficiency showed a strong inverse correlation with disability severity (EDSS). Patients with clinical progression demonstrated marked reductions in network integration and segregation, alongside increased characteristic path length. Machine learning models achieved robust prediction of upper limb functional decline, with ensemble-based methods performing best (balanced accuracy > 80%, AUC-ROC up to 0.85). A limited subset of connections accounted for a disproportionate share of predictive power, predominantly involving frontoparietal associative networks, thalamocortical pathways, and inter-hemispheric connections. In a longitudinal subset, network-level alterations preceded measurable clinical deterioration by several months.

conclusionsSynthetic structural connectivity derived from routine volumetric MRI captures clinically relevant network-level disruption in multiple sclerosis and enables accurate prediction of functional progression. By bridging network neuroscience with widely accessible imaging data, this framework provides a pragmatic alternative for connectomic analysis when diffusion imaging is unavailable and supports a network-based understanding of disease evolution in MS.

Indexed as

clinical progressiondisability severityinter-hemispheric connectionsmachine learning modelsnetwork vulnerability

Identifiers

PMID41900977
PMCPMC13028392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.